TEL AVIV, Israel, Feb. 03, 2025 (GLOBE NEWSWIRE) -- Chemomab Therapeutics Ltd. (Nasdaq: CMMB) (Chemomab), a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need, today announced that CEO Dr. Adi Mor and other members of its senior management team will deliver a corporate presentation and participate in one-on-one investor meetings at the virtual Oppenheimer 35th Annual Healthcare Life Sciences Conference on February 11, 2025. The Oppenheimer Conference presentation will be webcast live and will be available on the investor relations section of the Chemomab website for 90 days.
| Oppenheimer 35th Annual Healthcare Life Sciences Conference | |
| Date: | February 11, 2025 |
| Time: | 8:00 am ET |
| Venue: | Virtual |
| Format: | Webcast presentation |
| Webcast Link: | https://wsw.com/webcast/oppenheimer39/cmmb/2752408 |
| Information: | This email address is being protected from spambots. You need JavaScript enabled to view it. |
About Chemomab Therapeutics Ltd.
Chemomab is a clinical stage biotechnology company developing innovative therapeutics for fibro-inflammatory diseases with high unmet need. Based on the unique role of the soluble protein CCL24 in promoting fibrosis and inflammation, Chemomab developed CM-101, a first-in-class dual activity monoclonal antibody that neutralizes CCL24 and has demonstrated disease-modifying potential. In clinical and preclinical studies, CM-101 has been shown to have a favorable safety profile and has been generally well-tolerated, with the potential to treat multiple severe and life-threatening fibro-inflammatory diseases. Chemomab has reported positive results from four clinical trials of CM-101 in patients. Based on recent positive data from its Phase 2 SPRING trial in primary sclerosing cholangitis (PSC), the company expects two milestones in early 2025 – achieving a clear FDA registrational pathway for the planned CM-101 Phase 3 pivotal trial and reporting data from the SPRING trial open label extension. Chemomab is targeting initiation of the PSC Phase 3 trial before the end of the year. CM-101 has received FDA and EMA Orphan Drug and FDA Fast Track designations for the treatment of PSC. Chemomab’s CM-101 program for the treatment of systemic sclerosis is Phase 2-ready with an open U.S. IND. For more information, visit: chemomab.com.
Contacts:
Media and Investors:
Barbara Lindheim
Consulting Vice President, Investor & Public Relations, Strategic Communications
Phone: +1 917-355-9234
This email address is being protected from spambots. You need JavaScript enabled to view it.
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$1.38 |
| Daily Change: | -0.01 -0.72 |
| Daily Volume: | 42,897 |
| Market Cap: | US$26.030M |
March 06, 2025 March 03, 2025 November 14, 2024 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...
CLICK TO LEARN MORE
